Say Hello!
Don’t be shy.

   

News

Great news, at BioCity based Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in...

BioCity based XenoGesis’ Global Head of Business Development, Dr Rachel Hemsley has joined the University of Oxford’s Medical Sciences Experts in Residence (ExIR) scheme. The Experts in Residence programme is managed by the Medical Science Division’s Translational Research Office, Business Development & Partnering team and Oxford University Innovation. It aims to...

MediCity, Nottingham based Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, today announces that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.  John von Benecke has...

Supporting the discovery and development of new therapeutics during the pandemic Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement...

X
X
X
X